BCAL Diagnostics Limited (AU:BDX) has released an update.
BCAL Diagnostics Limited is making significant strides in breast cancer diagnostics, having raised $10.5 million through an oversubscribed placement to fund the commercialization of its innovative blood test. The company has nearly completed its SENSIBLE-3 study, commenced the BREASTEST clinical validation study, and invested in advanced laboratory equipment, increasing its testing capacity. These developments highlight BCAL’s commitment to enhancing diagnostic efficiency and accuracy for breast cancer patients.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.
